A CARA unified record still needs process-specific validation

Define intended use below the platform label

The direct answer is that validation should attach to each intended use and configuration, not to the statement that the platform is unified. A regulatory product record used for submission planning, a quality record used for a change control, a safety record used in a case, and a clinical record used in a trial may share master data while serving different users, rules, clocks, calculations, signatures, reports, and regulated decisions. The inventory should name the exact process, population, jurisdiction, risk, configuration, integration, output, and accountable owner.

Shared architecture can reduce interfaces and duplicate entry, but it can also propagate a bad value or permission more widely. Define which attributes are authoritative, which are reused, which are process-specific, and what happens when two functions need different valid values at the same time. A product name, status, organization, market, document version, or effective date should not become globally mutable without an approved ownership and conflict model.

Reconcile migration before declaring continuity

A migration record should cover source systems, extracts, field and relationship mappings, transforms, exclusions, duplicate handling, metadata, audit histories, attachments, signatures, record counts, checksums, exceptions, and final delta load. Sampling only records that imported cleanly can miss broken links, lost versions, invalid dates, inaccessible files, or histories that no longer explain who changed what. Reconciliation needs predefined acceptance thresholds and documented disposition of every exception class.

Legacy and target status must remain separate until cutover is approved. Freeze windows, concurrent updates, failed loads, rollback, retained read access, archival obligations, and decommissioning should be tested. If one shared CARA record replaces several legacy objects, the team should prove how each prior identifier and business context can be recovered. A successful technical load is not evidence that every regulated record is complete, readable, correctly related, or fit for its new intended use.

Validate configured controls and evidence

Risk-based testing should trace representative normal, boundary, missing-data, conflicting-data, unauthorized, failed-interface, and recovery cases through the configured workflow. Review roles, segregation, electronic signatures, effective dating, notifications, calculations, reports, audit trail, exports, and retention. Where AI or automation is enabled, identify the function, inputs, model or rule version, permitted output, human review, error handling, monitoring, and change trigger rather than treating platform governance as proof of each output.

Supplier documentation and base-platform testing can support the evidence package, but the organization still needs to establish its configuration, data, interfaces, procedures, training, infrastructure choices, and intended use. Changes should be assessed for impacted requirements, tests, records, integrations, reports, and users. A single platform release may affect functions differently, so one global validated status should not replace process-specific impact assessment and approval.

Test one shared change across four functions

A representative evaluation should change a shared product attribute used by regulatory, quality, safety, and clinical workflows. Introduce a conflicting local value, restrict one user's access, fail one integration, reopen a completed record, and update a controlled document after its effective date. Reviewers should reproduce the authoritative value, permitted reuse, function-specific decision, audit history, notification, exception, and validation impact without erasing the earlier state.

Generis's official CARA page supports the attributed positioning about a unified information space, connected regulated functions, governed workflows, audit trails, migration approach, validation evidence, permissions, and customer testing responsibility. It does not establish a particular configuration, data migration, intended use, validation state, regulatory compliance, inspection result, product quality, safety conclusion, or clinical outcome. Qualified quality, regulatory, safety, clinical, validation, information-technology, privacy, security, and legal owners retain their decisions.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.